Latest Imprimis Pharmaceuticals Inc. Stories
Dropless Cataract Therapy now available in California, Nevada, Oregon, and Hawaii SAN DIEGO, Dec. 3, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc.
Agreement to acquire Park Compounding marks an important milestone and a significant step forward to achieving nationwide distribution capability for Imprimis' patent-pending ophthalmic and urologic
Patent-pending ophthalmic formulation revenues increased over 190% compared to the second quarter 2014 SAN DIEGO, Nov. 12, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc.
Agreement represents the first distributor relationship outside the mainland United States for the company's ophthalmic formulations, which are now available by prescription in 36 states and US territories
Patented formulation of alkalized lidocaine and heparin has been prescribed as a compounded drug for individual patients in different dosages in thousands of insurance reimbursed bladder instillation
Dropless cataract surgery created a "buzz" and was a "hot topic" at this year's AAO meeting SAN DIEGO, Oct. 24, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc.
-- Go Dropless(TM) campaign continues its momentum as cataract surgeons embrace the benefits of "going dropless" for their patients -- SAN DIEGO, Oct.
SAN DIEGO, Sept. 16, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc.
SAN DIEGO, Sept. 8, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc.
- Imprimis' proprietary ophthalmic compounded formulations now available by prescription in 32 states and territories - SAN DIEGO, July 24, 2014 /PRNewswire/ --
- A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.